Hangzou, China-based Venus Medtech is paying $300m to acquire Israeli transcatheter valve developer Cardiovalve to help advance transcatheter valve replacement technology in Europe, China and the US.
Cardiovalve is developing a transcatheter valve replacement device and transfemoral delivery system to treat mitral and tricuspid valve regurgitation. Cardiovalve said its system is suitable for about 95% of the...